Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.80 Consensus Price Target from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $43.80.

A number of research firms have issued reports on COLL. Piper Sandler restated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $33.35 on Monday. The business’s 50-day simple moving average is $30.54 and its 200 day simple moving average is $34.09. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of 14.38 and a beta of 0.82. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Collegium Pharmaceutical by 15.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 27,150 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 3,652 shares during the period. JPMorgan Chase & Co. increased its stake in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after buying an additional 64,958 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Collegium Pharmaceutical by 13.4% in the third quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,620 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.